ArticleFrontiers in digital health2026
Real-world validation of an AI-based non-mydriatic fundus camera in the diagnosis of diabetic retinopathy in Liberia.
Article in Frontiers in digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Diabetic retinopathy (DR) is a leading cause of preventable vision loss, yet access to retinal screening remains limited in low-resource settings such as Liberia. This study evaluated the real-world diagnostic performance of an offline artificial intelligence (AI)-enabled smartphone-based non-mydriatic fundus camera for detecting referable diabetic retinopathy in a routine general outpatient screening setting in Liberia. Methods: This prospective study was conducted at the General Outpatient Department of John F. Kennedy Medical Center, Monrovia, Liberia. Adults aged 18 years and older were recruited through convenience sampling and underwent non-mydriatic fundus imaging using the Remidio Fundus on Phone (FOP-NM-10) integrated with an offline AI system. Fundus images were independently assessed by two trained optometrists using the International Clinical Diabetic Retinopathy (ICDR) classification, with disagreements adjudicated by a senior retinal ophthalmologist. Referable DR was defined as moderate non-proliferative DR, severe non-proliferative DR, or proliferative DR. Diagnostic performance was evaluated at the participant level among participants with at least one gradable eye. Results: A total of 1,612 participants were enrolled, of whom 1,357 were included in the final analytical cohort. Of these, 1,198 (88.3%) had at least one gradable eye and were included in the diagnostic-performance analysis. Eleven participants were classified as having referable DR by the human reference standard. The AI system correctly classified 10 of these 11 participants, yielding a sensitivity of 90.9% (95% CI, 58.7%-100%). Among 1,187 participants without referable DR, 1,183 were correctly classified as negative, resulting in a specificity of 99.7% (95% CI, 99.1%-99.9%). The positive predictive value was 71.4% (95% CI, 41.9%-91.6%), and the negative predictive value was 99.9% (95% CI, 99.5%-99.9%). Conclusions: In this prospective real-world study, the offline AI-based non-mydriatic fundus camera showed high sensitivity and specificity for detecting referable diabetic retinopathy among participants with at least one gradable eye in a general outpatient setting in Liberia. These findings support its feasibility for AI-assisted detection of referable DR in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.